Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.

Journal of cachexia, sarcopenia and muscle - 1 Aug 2018

Kays Joshua K, Shahda Safi, Stanley Melissa, Bell Teresa M, O'Neill Bert H, Kohli Marc D, Couch Marion E, Koniaris Leonidas G, Zimmers Teresa A

Abstract excerpt

BACKGROUND: By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin therapy. METHODS: We performed a retrospective review of 53 patients with advanced PDAC on 5-fluorouracil,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Composition
Share to Body Weights and Measures

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cachexia

Share to Carcinoma, Pancreatic Ductal

Share to Fluorouracil

Share to Irinotecan

Share to Leucovorin

Share to Oxaliplatin

Source

Open in PubMed Open full text

Identifiers

PMID: 29978562
DOI: 10.1002/jcsm.12307
PMCID: PMC6104116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.PMID 29978562Read ↗

Animal models of xenograft-induced cachexia of patient-derived pancreatic cancer: exploring potential new biomarkers and treatment targetsSemantic proximity Read ↗

Modeling Human Cancer-induced CachexiaSemantic proximity Read ↗

Identification of circulating protein biomarkers for pancreatic cancer cachexiaSemantic proximity Read ↗

Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia modelSemantic proximity Read ↗

Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent PathwaysSemantic proximity Read ↗

Profiling of Matched Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent PathwaysSemantic proximity Read ↗

Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscleSemantic proximity Read ↗

New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss.Semantic proximity Read ↗

Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose <i>de novo</i> lipogenesisSemantic proximity Read ↗

Anatomical dynamics define cancer cachexia subtypes and identify systemic inflammation as a marker of lethal wastingSemantic proximity Read ↗

Transcriptome and microRNAome profiling of human skeletal muscle in pancreatic cancer cachexiaSemantic proximity Read ↗

Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.